Ivabradine Actavis (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the spontaneous depolarisation of pacemaker cells slows, leading to a reduction in resting heart rate without decreasing the strength of heart contractions.

The dose of Ivabradine Actavis is determined by the prescribing clinician based on the patient’s clinical status, heart‑rate target, and tolerability. The prescriber will select the appropriate strength and dosing schedule according to current guidelines.

Safety data for ivabradine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare professional should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s condition.

Store at room temperature: keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and avoid exposure to temperatures above 25 °C. Do not refrigerate or freeze the product.

Ivabradine Actavis is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Dosing times are typically spaced 12 hours apart, but the exact schedule is set by the prescribing physician.

The most serious risks include symptomatic bradycardia, severe hypotension, atrial fibrillation, and persistent visual disturbances such as phosphenes. Patients should be educated to report any episodes of dizziness, fainting, or visual changes promptly.

Ivabradine should not be used in patients with a resting heart rate below 50 bpm, those with acute decompensated heart failure, severe hepatic impairment, sick sinus syndrome, or in combination with strong CYP3A4 inhibitors. Contra‑indications are confirmed by the treating physician.